This HTML5 document contains 58 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/AHFS/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01160/identifier/wikipedia/
n19http://linked.opendata.cz/resource/drugbank/company/
n4http://linked.opendata.cz/resource/mesh/concept/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01160/identifier/pharmgkb/
n6http://linked.opendata.cz/resource/drugbank/drug/DB01160/identifier/pubchem-compound/
n14http://bio2rdf.org/drugbank:
n20http://linked.opendata.cz/resource/drugbank/drug/DB01160/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/drug/DB01160/identifier/kegg-drug/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01160/identifier/drugbank/
n21http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/ontology/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/mesh/
n9http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/drugbank/drug/DB01160/identifier/chemspider/
n17http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01160
rdf:type
n7:Drug
n7:description
The tromethamine (THAM) salt of the naturally occurring prostaglandin F2 alpha, dinoprost tromethamine occurs as a white to off-white, very hygroscopic, crystalline powder. Dinoprost tromethamine may also be known as dinoprost trometamol, PGF2 alpha THAM, or prostaglandin F2 alpha tromethamine.
n7:group
approved
n7:halfLife
The half-life of dinoprost in amniotic fluid is 3 to 6 hours. The plasma half-life of dinoprost after intravenous administration is reported to be less than 1 minute.
n7:indication
Used for aborting second-trimester pregnancy (between the twelfth to eighteenth week of gestation) and in incomplete abortion or for therapeutic abortion in cases of intrauterine fetal death and congenital abnormalities incompatible with life. Also used at low-doses for medically indicated induction of labor at term. Also injected intra-arterially for use as a vasodilator to assist in angiography.
owl:sameAs
n14:DB01160 n21:DB01160
dcterms:title
Dinoprost Tromethamine
adms:identifier
n6:5282415 n8:D01352 n10:4445570 n11:DB01160 n15:PA164781385 n16:Prostaglandin_F2alpha n20:46509164
n7:mechanismOfAction
Dinoprost tromethamine appears to act directly on the myometrium, but this has not been completely established. Dinoprost stimulates myometrial contractions (via its interaction with the prostaglandin receptors) in the gravid uterus that are similar to the contractions that occur in the term uterus during labor. These contractions are usually sufficient to cause abortion. Uterine response to prostaglandins increases gradually throughout pregnancy. Dinoprost also facilitates cervical dilatation and softening.
n7:packager
n19:271B4BB9-363D-11E5-9242-09173F13E4C5
n7:synonym
Prostaglandin F2a tromethamine Prostin F2 Alpha PGF2-alpha THAM Prostaglandin F2alpha tham Prostaglandin F2-alpha THAM Dinoprost trometamol PGF2alpha THAM
n7:toxicity
Although overdose by intra-amniotic administration of dinoprost has not been reported, exaggeration of the nausea, vomiting, and diarrhea that occur with normal doses would be expected.
n17:hasAHFSCode
n18:76-00-00
n7:synthesisReference
Morozowich, W.; U.S. Patent 3,657,327; April 18,1972; assigned to The Upjohn Company.
n3:hasConcept
n4:M0056434
n7:IUPAC-Name
n9:271B4BBB-363D-11E5-9242-09173F13E4C5
n7:InChI
n9:271B4BC1-363D-11E5-9242-09173F13E4C5
n7:Molecular-Formula
n9:271B4BC0-363D-11E5-9242-09173F13E4C5
n7:Molecular-Weight
n9:271B4BBD-363D-11E5-9242-09173F13E4C5
n7:Monoisotopic-Weight
n9:271B4BBE-363D-11E5-9242-09173F13E4C5
n7:SMILES
n9:271B4BBF-363D-11E5-9242-09173F13E4C5
n7:Water-Solubility
n9:271B4BD1-363D-11E5-9242-09173F13E4C5
n7:logP
n9:271B4BBA-363D-11E5-9242-09173F13E4C5 n9:271B4BD3-363D-11E5-9242-09173F13E4C5
n7:H-Bond-Acceptor-Count
n9:271B4BC7-363D-11E5-9242-09173F13E4C5
n7:H-Bond-Donor-Count
n9:271B4BC8-363D-11E5-9242-09173F13E4C5
n7:InChIKey
n9:271B4BC2-363D-11E5-9242-09173F13E4C5
n7:Polar-Surface-Area--PSA-
n9:271B4BC3-363D-11E5-9242-09173F13E4C5
n7:Polarizability
n9:271B4BC5-363D-11E5-9242-09173F13E4C5
n7:Refractivity
n9:271B4BC4-363D-11E5-9242-09173F13E4C5
n7:Rotatable-Bond-Count
n9:271B4BC6-363D-11E5-9242-09173F13E4C5
n7:absorption
Slowly absorbed from the amniotic fluid into systemic circulation.
n7:affectedOrganism
Humans and other mammals
n7:casRegistryNumber
38562-01-5
n7:category
n7:Bioavailability
n9:271B4BCD-363D-11E5-9242-09173F13E4C5
n7:Ghose-Filter
n9:271B4BCF-363D-11E5-9242-09173F13E4C5
n7:MDDR-Like-Rule
n9:271B4BD0-363D-11E5-9242-09173F13E4C5
n7:Melting-Point
n9:271B4BD2-363D-11E5-9242-09173F13E4C5
n7:Number-of-Rings
n9:271B4BCC-363D-11E5-9242-09173F13E4C5
n7:Physiological-Charge
n9:271B4BCB-363D-11E5-9242-09173F13E4C5
n7:Rule-of-Five
n9:271B4BCE-363D-11E5-9242-09173F13E4C5
n7:Traditional-IUPAC-Name
n9:271B4BBC-363D-11E5-9242-09173F13E4C5
n7:pKa--strongest-acidic-
n9:271B4BC9-363D-11E5-9242-09173F13E4C5
n7:pKa--strongest-basic-
n9:271B4BCA-363D-11E5-9242-09173F13E4C5